ALID (Allied) Common Stock: $0.01 Mil (As of Nov. 2024)


What is Allied Common Stock?

Allied ALID -99.80% Common Stock is $0.01 Mil as of Nov. 2024.

Allied's quarterly common stock stayed the same from May. 2024 ($0.01 Mil) to Aug. 2024 ($0.01 Mil) but then increased from Aug. 2024 ($0.01 Mil) to Nov. 2024 ($0.01 Mil).

Allied's annual common stock increased from Aug. 2022 ($0.01 Mil) to Aug. 2023 ($0.01 Mil) and increased from Aug. 2023 ($0.01 Mil) to Aug. 2024 ($0.01 Mil).

Allied Common Stock Historical Data

* Premium members only.

The historical data trend for Allied's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allied Common Stock Chart

Allied Annual Data
Trend Mar18 Mar19 Aug20 Aug21 Aug22 Aug23 Aug24
Common Stock
Get a 7-Day Free Trial 0.01 0.01 0.01 0.01 0.01

Allied Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Allied Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.01 Mil mean?
Allied (ALID) has a Common Stock of $0.01 Mil as of Nov. 2024. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Allied and its competitors.
Is Allied's Common Stock too high?
Allied's current Common Stock is $0.01 Mil.
How does Allied's Common Stock compare to CBDY and PLSH?
Allied's Common Stock of $0.01 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Allied and its competitors. Allied's current Common Stock is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied stock overvalued right now?
Allied (ALID) has a current Common Stock of $0.01 Mil. The current Common Stock is $0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Allied (ALID), the current Common Stock is $0.01 Mil as of Nov. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allied Business Description

Address 460 Doyle Avenue, Suite 200, Kelowna, BC, CAN, V1Y OC2
Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments, which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised of sales of cannabis products.